Alzheimer’s Disease: Neuropathology, Epidemiology, and Treatments
Neuropathology : the study of diseases related to nervous system
Epidemiology : the study of how often diseases occur in different groups of people
Although this is related to my field of study Alzheimer disease is a difficult subject to research and it can affect people differently, as dementia is not the same for everyone. Alzheimer disease, a very complicated disease which affects over 57 million people worldwide WHO and tends to start off mild and progress with age. Let’s start by clarifying the difference. Whilst dementia is a general term to describe the progressive and persistent loss of intellectual function and memory Alzheimer’s disease affects specific parts of the brain.
Affected Brain Regions:
Alzheimer’s disease (AD) causes progressive neuro-degeneration that begins in specific brain regions. Early in AD, neurons in the medial temporal lobe (particularly the transentorhinal and entorhinal cortices) and hippocampus start to degenerate and eventually stop functioning nia.nih.gov. These areas are essential for memory consolidation; their loss impairs formation of new memories. Over time AD spreads to association cortices (parietal, temporal, and frontal lobes) affecting language, reasoning, and behaviour nia.nih.gov. Widespread neuronal loss eventually leads to brain atrophy (shrinkage) and enlarged ventricles nia.nih.gov. The diagram below illustrates the entorhinal cortex (EC) and hippocampus, the first regions hit by Alzheimer’s pathology.
Figure: In Alzheimer’s, the disease process begins in the narrow transentorhinal region and spreads to the adjacent entorhinal cortex and hippocampus (memory centres) nia.nih.gov. These areas degenerate first before pathology extends to cortical regions.
Pathological Mechanisms:
AD is characterised by abnormal protein accumulations and inflammation. The amyloid hypothesis posits that cleavage of amyloid precursor protein produces toxic β-amyloid (Aβ) peptides that aggregate into extracellular plaque nia.nih.gov. In parallel, tau proteins become hyperphosphorylated and form neurofibrillary tangles inside neurons nia.nih.gov. Plaques and tangles disrupt synaptic function and nutrient transport, causing neurons to malfunction and die nia.nih.gov. As neurons perish, synaptic networks break down and affected brain regions shrink nia.nih.gov. Microglia and astrocytes (brain immune cells) normally clear debris, but in AD they malfunction, leading to chronic neuroinflammation that exacerbates damage nia.nih.gov. Thus, AD arises from a complex interplay of amyloid deposition, tau pathology, neuronal loss, and inflammatory processes nia.nih.gov. this is an extremely complicated process which is difficult to understand for me and even professionals who focus in this field and are trying to understand this mechanism in a clear manner in order to develop medications to treat it therefor lots more research is required in this field to help boost our understanding and treatment methods.
Global and UK Epidemiology:
Worldwide, dementia affects over 55 million people as of (2020–21) who.int. Alzheimer’s disease is the most common form, accounting for about 60–70% of all dementia cases mayoclinic.org. The global dementia burden is rising rapidly: cases are projected to more than double by 2050 alzint.orgalzheimers.org.uk. Most of the increase is in low- and emerging-income countries; currently over 60% of dementia patients live in such regions who.int alzint.org. In 2020 there were ~55 million people with dementia worldwide, rising to an estimated 78 million by 2030 and 139 million by 2050 alzint.org.
In the UK, about 1 million people have dementia today, and this is expected to reach ~1.4 million by 2040 alzheimers.org.uk. AD is the largest component (the UK Alzheimer’s Society notes AD is the most common dementia) alzheimers.org.uk. Prevalence rises steeply with age: roughly 2% of people aged 65–69 have dementia and risk roughly doubles every five years thereafter alzheimers.org.uk. About one-third of today’s UK newborns may develop dementia in their lifetimes alzheimers.org.uk. Alzheimer’s imposes a heavy societal cost – dementia care costs the UK an estimated £42 billion/year (2024) and is projected to exceed £90 billion by 2040 alzheimers.org.uk. Over 70% of UK care-home residents have dementia or severe memory problems alzheimers.org.uk. Early-onset dementia (onset <65 years) currently affects >70,000 people in the UK alzheimers.org.uk.
Risk Factors and High-Risk Groups:
The strongest risk factor for AD is advanced age alzheimers.org.uk. After age 65, AD risk roughly doubles every 5 years alzheimers.org.uk. However, it is not a normal part of aging. Genetics also plays a major role meaning some ethnic groups are more susceptible to AD : having one or two copies of the APOE ε4 allele greatly increases risk alzheimers.org.uk. In fact, about two-thirds of UK AD patients carry an APOE ε4 variant alzheimers.org.uk. Rare familial mutations in APP, PSEN1 or PSEN2 cause early-onset AD but account for <1% of cases alzheimers.org.uk. People with Down syndrome (trisomy 21, which includes an extra APP gene) have a markedly higher risk of Alzheimer’s alzheimers.org.uk.
Cardiovascular and metabolic factors also raise AD risk. High blood pressure, diabetes, obesity, and stroke increase dementia risk by damaging cerebrovascular health alzheimers.org.uk. Lifestyle factors are important: for example, smoking and excessive alcohol use increase dementia risk alzheimers.org.uk. Low educational attainment (less “cognitive reserve”) and chronic social deprivation are linked to higher AD rates alzheimers.org.uk. Sex differences exist: about two-thirds of AD patients are women nature.com. Longevity explains much of this (women live longer), but even adjusted for age, women over 80 may have a higher susceptibility to AD alzheimers.org.uk nature.com. Traumatic brain injury also raises AD risk (noted in broader literature). In summary, the highest-risk populations are very elderly individuals, carriers of risk genes (especially APOE ε4), and those with cardiovascular or metabolic disease.
Early Warning Signs:
Alzheimer’s is insidious, so early symptoms are often subtle and unnoticeable. The hallmark initial deficit is short-term memory loss. A person may frequently forget recent conversations, appointments or events nhs.uk. They may repeatedly ask the same questions or misplace items in odd places nhs.uk. Word-finding difficulties emerge: struggling to recall names of familiar objects or people is common nhs.uk. Judgement and executive skills decline – for example, making poor decisions about money or time management nhs.uk. People may appear less flexible, hesitant to try new tasks, and more anxious or depressed than usual. Mood and personality changes (apathy, irritability, social withdrawal) often accompany cognitive deficits nhs.uk. Disorientation in time or place may occur even in early AD. Because these symptoms can be mistaken for normal aging, clinical diagnosis often lags behind onset. Nonetheless, vigilance for persistent memory lapses and cognitive changes is crucial, since an earlier diagnosis allows earlier intervention, planning and treatment nhs.uk nhs.uk.
Treatment and Management (2024–2025):
No cure exists for Alzheimer’s disease alzheimers.org.uk. Treatments focus on symptom relief and support for patients and their loved ones. Pharmacological therapies: The mainstay drugs are acetylcholinesterase inhibitors and memantine. Donepezil, rivastigmine, and galantamine boost acetylcholine levels to help cognition and function; they are recommended for mild-to-moderate AD alzheimers.org.uk nice.org.uk. Memantine, an NMDA-receptor antagonist, is indicated for moderate-to-severe AD alzheimers.org.uk nice.org.uk. These medications can stabilise or modestly improve symptoms for months in some patients but like any medication they come with their own side effects alzheimers.org.uk, and their effects eventually fade as the body becomes tolerant of the drugs, they do not halt disease progression alzheimers.org.uk alzheimers.org.uk. Other drugs are used off-label to manage behavioural symptoms (e.g. depression, agitation), but with caution due to side effects.
Breakthrough therapies: Recent advances have produced the first disease-modifying drugs targeting amyloid. In the U.S., the monoclonal antibodies lecanemab and donanemab were FDA-approved (2023) for early-stage AD. These agents reduce amyloid plaques and have shown slower cognitive decline in clinical trials nia.nih.gov. In the UK, lecanemab (marketed as Leqembi) gained MHRA approval in 2024, though NICE has so far not recommended its NHS use pending cost-effectiveness analysis alzheimers.org.uk. Donanemab is also under review. Aducanumab (Aduhelm) was a similar anti-amyloid drug approved in the U.S. in 2021 but remains controversial and is not used in the UK. Besides antibodies, dozens of other drugs (targeting tau, inflammation, metabolism, etc.) are in clinical trials and testing– over 120 candidate therapies are in testing worldwide alzheimers.org.uk.
Non-Pharmacological Therapies: Non-drug interventions are important, especially in early-to-mid AD. Cognitive Stimulation Therapy (CST): NICE recommends structured group cognitive stimulation for people with mild-moderate dementia nice.org.uk. CST (and similar cognitive training) can improve cognition and quality of life, at least temporarily. Occupational therapy and reminiscence therapy are also used to maintain daily function nice.org.uk. Regular social interaction, physical exercise and a Mediterranean/MIND diet have been shown in studies to modestly reduce cognitive decline risk (though evidence is still evolving). In practice, care focuses on maximising independence: memory aids, safe home environments, routine, and social support help patients cope as the disease advances. Carer education, support groups, and legal planning are also key.
Overall, current AD treatments are symptomatic, but the landscape is rapidly evolving. The recent amyloid-targeting drugs represent a paradigm shift, even if access is limited. Research into tau vaccines, gene therapies, and neuroprotective strategies continues. Given the disease’s complexity, a multi modal approach (combining lifestyle, pharmacological and supportive care) is advocated in order to reduce cognitive decline and other negative symptoms of AD. Early diagnosis and risk-factor control (e.g. managing hypertension, diabetes) remain important prevention strategies. As one UK dementia researcher noted, we are “at a tipping point” in Alzheimer’s research alzheimers.org.uk, but widespread implementation of breakthroughs will require more funding and evidence in order to be safely implemented.
Key Takeaways:
- Alzheimer’s is characterised by amyloid plaques, tau tangles, and selective neuron death, starting in the entorhinal cortex and hippocampus nia.nih.govnia.nih.gov.
- Globally ~55–57 million people have dementia (2020–21), with Alzheimer’s accounting for ~60–70% mayoclinic.org who.int. Numbers are rising fastest in low/ emerging-income regions alzint.org. In the UK ~1 million have dementia now, projected to ~1.4 million by 2040 alzheimers.org.uk.
- Older age is the greatest risk factor alzheimers.org.uk. Genetics (e.g. APOE ε4) and vascular health strongly influence AD risk. Women are disproportionately affected accounting for (≈2/3 of cases) nature.com.
- Early signs include persistent memory lapses (new events, words, names) and subtle cognitive/behavioral changes nhs.uknhs.uk. Formal cognitive testing and imaging help confirm diagnosis.
- Treatments (2024) include cholinesterase inhibitors and memantine alzheimers.org.uk nice.org.uk, which modestly relieve symptoms. New anti-amyloid drugs (lecanemab, donanemab) offer hope for slowing decline however note almost all drugs come with side effects nia.nih.gov. Non-drug therapies (cognitive stimulation, exercise, healthy diet) are recommended to support function.
- Despite progress, Alzheimer’s remains incurable alzheimers.org.uk. Continuous research, risk reduction, and timely diagnosis are critical to improve outcomes.
- multi-model approaches have been the most successful at combating the effects of AD
Reference list
Alzheimer’s Disease International. (n.d.). Dementia statistics. Alzheimer’s Disease International.
Alzheimer’s Society. (2024). How many people have dementia in the UK? Retrieved from alzheimers.org.uk
Alzheimer’s Society. (2024). Facts for the media about dementia. Alzheimer’s Society UK.
Alzheimer’s Society. (n.d.). Risk factors for Alzheimer’s disease. Alzheimer’s Society UK.
Alzheimer’s Society. (n.d.). What can increase a person’s risk of dementia? Alzheimer’s Society UK.
Alzheimer’s Society. (n.d.). Types of dementia: Alzheimer’s disease. Alzheimer’s Society UK.
Alzheimer’s Society. (2024). Dementia: Press coverage of first MHRA approval of lecanemab. Alzheimer’s Society UK (media guide).
Mayo Clinic. (n.d.). Alzheimer’s disease – Symptoms and causes. Mayo Clinic.
National Institute on Aging. (n.d.). What happens to the brain in Alzheimer’s disease? U.S. Department of Health & Human Services, National Institutes of Health.
National Institute for Health and Care Excellence. (2018). Dementia: Assessment, management and support for people living with dementia and their carers (NICE Guideline NG97).
NHS. (n.d.). Alzheimer’s disease: Symptoms. NHS.uk.
World Health Organization. (2023). Dementia. Retrieved from who.int
Moutinho, S. (2025). Women twice as likely to develop Alzheimer’s disease as men – but scientists do not know why. Nature Medicine, 31, 704–707. nature.com
Cholinesterase inhibitors for Alzheimer’s disease (donepezil, galantamine, rivastigmine) and memantine for Alzheimer’s disease [Technology Appraisal Guidance No. 217]. (2011). National Institute for Health and Care Excellence.
U.S. National Library of Medicine. (n.d.). Alzheimer’s disease in people with Down syndrome. National Institute on Aging. Retrieved from [nia.nih.gov]
United Kingdom Government. (2023). Primary Care Dementia and COVID-19 rehabilitation data. NHS Digital. (Contains updated diagnosis rates.)
Alzheimer’s Research UK. (2022). World Alzheimer Report 2023: journey through the brain. report.